EP1496931A4 - Verfahren zur behandlung einer autoimmunkrankheit mit einem löslichen ctla4-molekül und einem dmard oder nsaid - Google Patents

Verfahren zur behandlung einer autoimmunkrankheit mit einem löslichen ctla4-molekül und einem dmard oder nsaid

Info

Publication number
EP1496931A4
EP1496931A4 EP03747047A EP03747047A EP1496931A4 EP 1496931 A4 EP1496931 A4 EP 1496931A4 EP 03747047 A EP03747047 A EP 03747047A EP 03747047 A EP03747047 A EP 03747047A EP 1496931 A4 EP1496931 A4 EP 1496931A4
Authority
EP
European Patent Office
Prior art keywords
dmard
nsaid
treating
methods
autoimmune disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03747047A
Other languages
English (en)
French (fr)
Other versions
EP1496931A1 (de
Inventor
Robert Cohen
Suzette Carr
David Hagerty
Robert J Peach
Jean-Claude Becker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of EP1496931A1 publication Critical patent/EP1496931A1/de
Publication of EP1496931A4 publication Critical patent/EP1496931A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP03747047A 2002-04-19 2003-04-18 Verfahren zur behandlung einer autoimmunkrankheit mit einem löslichen ctla4-molekül und einem dmard oder nsaid Withdrawn EP1496931A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US37385202P 2002-04-19 2002-04-19
US373852P 2002-04-19
US40724602P 2002-08-30 2002-08-30
US407246P 2002-08-30
PCT/US2003/012356 WO2003088991A1 (en) 2002-04-19 2003-04-18 Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid

Publications (2)

Publication Number Publication Date
EP1496931A1 EP1496931A1 (de) 2005-01-19
EP1496931A4 true EP1496931A4 (de) 2009-07-01

Family

ID=29254538

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03747047A Withdrawn EP1496931A4 (de) 2002-04-19 2003-04-18 Verfahren zur behandlung einer autoimmunkrankheit mit einem löslichen ctla4-molekül und einem dmard oder nsaid

Country Status (4)

Country Link
EP (1) EP1496931A4 (de)
AU (1) AU2003243152A1 (de)
CA (1) CA2482042A1 (de)
WO (1) WO2003088991A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006108035A1 (en) * 2005-04-06 2006-10-12 Bristol-Myers Squibb Company Methods for treating immune disorders associated with graft transplantation with soluble ctla4 mutant molecules
US8501704B2 (en) 2005-11-08 2013-08-06 Sarepta Therapeutics, Inc. Immunosuppression compound and treatment method
CA2628093A1 (en) * 2005-11-08 2007-05-18 Avi Biopharma, Inc. Antisense oligonucleotide analog compounds targeting proprocessed ctla-4 mrna
PL2253644T3 (pl) 2005-12-20 2014-04-30 Bristol Myers Squibb Co Kompozycje i sposoby wytwarzania kompozycji
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
US9707284B2 (en) 2006-06-01 2017-07-18 The Regents Of The University Of California Formulations of peptides and chloroquines for the treatment of pathogenic immune responses in immune mediated diseases
WO2010042433A1 (en) 2008-10-06 2010-04-15 Bristol-Myers Squibb Company Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
US20140147418A1 (en) * 2011-04-15 2014-05-29 The Us Of America, As Represented By The Secretary Department Of Health And Human Services Aav mediated ctla-4 gene transfer to treat sjogren's syndrome
CA2833623A1 (en) 2011-04-20 2012-10-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Aav mediated exendin-4 gene transfer to salivary glands to protect subjects from diabetes or obesity
CA2882763C (en) 2012-08-31 2019-01-15 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Aav mediated aquaporin gene transer to treat sjogren's syndrome
US10195153B2 (en) 2013-08-12 2019-02-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
ES2809458T3 (es) 2014-07-17 2021-03-04 Pharmaceutical Manufacturing Res Services Inc Forma de dosificación llena de líquido, disuasoria del abuso y de liberación inmediata
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
US9757372B2 (en) * 2015-03-25 2017-09-12 Taiwanj Pharmaceuticals Co., Ltd. Toll-like receptor 4 antagonists and use in autoimmune liver diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002002638A2 (en) * 2000-07-03 2002-01-10 Bristol-Myers Squibb Company Methods for treating rheumatic diseases using a soluble ctla4 molecule

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5844095A (en) * 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
EP3029062A1 (de) * 2000-05-26 2016-06-08 Bristol-Myers Squibb Company Lösliche ctla4 mutante moleküle und verwendungen davon

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002002638A2 (en) * 2000-07-03 2002-01-10 Bristol-Myers Squibb Company Methods for treating rheumatic diseases using a soluble ctla4 molecule

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MORELAND L W ET AL: "COSTIMULATORY BLOCKADE IN PATIENTS WITH RHEUMATOID ARTHRITIS", ARTHRITIS AND RHEUMATISM, LIPPINCOTT, PHILADELPHIA, US, vol. 46, no. 6, 1 June 2002 (2002-06-01), pages 1470 - 1479, XP009066947, ISSN: 0004-3591 *
See also references of WO03088991A1 *

Also Published As

Publication number Publication date
EP1496931A1 (de) 2005-01-19
WO2003088991A9 (en) 2004-02-05
WO2003088991A1 (en) 2003-10-30
AU2003243152A1 (en) 2003-11-03
CA2482042A1 (en) 2003-10-30

Similar Documents

Publication Publication Date Title
EP1496931A4 (de) Verfahren zur behandlung einer autoimmunkrankheit mit einem löslichen ctla4-molekül und einem dmard oder nsaid
AU2003216507A8 (en) Methods, systems, and software for identifying functional bio-molecules
EP1556057A4 (de) Mittel und verfahren zur verstärkung der knochenbildung
EP1638432A4 (de) Werkzeugaufbewahrungssystem und verfahren
AU2003297908A8 (en) Articulated elements and methods for use
AU2003300783A8 (en) Vascular assist device and methods
AU2003228850A8 (en) Single trial detection in encephalography
AU2003302327A8 (en) System and method for below-market trading
AU2003283786A8 (en) Surgical tools and techniques for stimulation
AU2003225743A8 (en) Method and system for managing software licenses
AU2003285117A8 (en) Multiple-entity transaction systems and methods
AU2003223494A8 (en) Methods for detecting bcr-abl signaling activity in tissues using phospho- specific antibodies
AU2003268800A1 (en) Barking device and barking tool
EP1543324A4 (de) Verfahren und zusammensetzungen zur implantation von funktionalen schleifen in ein protein
GB0424591D0 (en) A system for and method for authenticating items
AU2003256526A1 (en) Arrangements and methods for treating a subject
GB2408530B (en) Well completion systems and methods
EP1545554A4 (de) Verfahren und zusammensetzungen zur behandlung von diabetes mellitus
AU2003227861A8 (en) Protein involved in cancer
AU2003237657A1 (en) Means and methods for improved treatment using "setrones"
AU2003301348A1 (en) Compositions and methods for diagnosing and treating autoimmune disease
HK1073370A1 (en) Method, system and software for journaling system objects
AU2003275240A8 (en) Methods and compositions for soluble cpg15
GB0224436D0 (en) Polypetides methods and means
AU2003280332A8 (en) Device and method for connecting objects

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20041105

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

A4 Supplementary search report drawn up and despatched

Effective date: 20090604

17Q First examination report despatched

Effective date: 20100614

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20101026